Critical Reviews in Therapeutic Drug Carrier Systems最新文献_第3页

A Narrative Review on Non-Invasive Drug Delivery of Teriparatide: A Ray of Hope. 特立帕肽无创给药研究述评:一线希望。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2023045480

Neeraj Mittal, Gajanand Sharma, Om Parkash Katare, Sanjay Kumar Bhadada

{"title":"A Narrative Review on Non-Invasive Drug Delivery of Teriparatide: A Ray of Hope.","authors":"Neeraj Mittal, Gajanand Sharma, Om Parkash Katare, Sanjay Kumar Bhadada","doi":"10.1615/CritRevTherDrugCarrierSyst.2023045480","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023045480","url":null,"abstract":"In the field of pharmaceutical biotechnology and formulation development, various protein and peptide-based drugs have been used for therapeutic and clinical implications. These are mainly given via parenteral routes like intravenous, subcutaneous or intramuscular delivery. Teriparatide, also known as PTH 1-34, is a U.S. Food & Drug Administartion-approved anabolic drug to treat osteoporosis is currently available in market only as subcutaneous injection. The quest for elimination of needle in case of given peptidal delivery to replace it with alternative routes like nasal, buccal, transdermal and pulmonary pathways has driven meticulous drug research. The pharmaceutical scientists are working on innovation and approaches involving new materials and methods to develop the formulations for protein and peptides by noninvasive routes. Lately, various approaches have been carried out which involve many strategies and technologies to deliver teriparatide via alternative routes. But, physicochemical instability, proteolytic degradation, low bioavailability, etc. are some obstacles to develop suitable delivery system for teriparatide. This review intends to gather the overall developments in delivery systems specific to teriparatide which meant for better convenience and avoids vulnerability of multiple subcutaneous injections. In addition, the article emphasizes on the successes to develop noninvasive technologies and devices, and new milestones for teriparatide delivery.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 6","pages":"117-140"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10019094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems. 利用新型载体系统探索环孢素治疗眼科适应症的潜力。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022043085

Garima Rawat, Shital Kolhe, Dhwani Rana, Sagar Salave, Derajram Benival

引用次数: 2

Impact of Nanotechnology on Differentiation and Augmentation of Stem Cells for Liver Therapy. 纳米技术对肝治疗干细胞分化和增强的影响。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2023042400

Ifrah Anwar, Usman Ali Ashfaq

{"title":"Impact of Nanotechnology on Differentiation and Augmentation of Stem Cells for Liver Therapy.","authors":"Ifrah Anwar, Usman Ali Ashfaq","doi":"10.1615/CritRevTherDrugCarrierSyst.2023042400","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023042400","url":null,"abstract":"The liver is one of the crucial organs of the body that performs hundreds of chemical reactions needed by the body to survive. It is also the largest gland of the body. The liver has multiple functions, including the synthesis of chemicals, metabolism of nutrients, and removal of toxins. It also acts as a storage unit. The liver has a unique ability to regenerate itself, but it can lead to permanent damage if the injury is beyond recovery. The only possible treatment of severe liver damage is liver transplant which is a costly procedure and has several other drawbacks. Therefore, attention has been shifted towards the use of stem cells that have shown the ability to differentiate into hepatocytes. Among the numerous kinds of stem cells (SCs), the mesenchymal stem cells (MSCs) are the most famous. Various studies suggest that an MSC transplant can repair liver function, improve the signs and symptoms, and increase the chances of survival. This review discusses the impact of combining stem cell therapy with nanotechnology. By integrating stem cell science and nanotechnology, the information about stem cell differentiation and regulation will increase, resulting in a better comprehension of stem cell-based treatment strategies. The augmentation of SCs with nanoparticles has been shown to boost the effect of stem cell-based therapy. Also, the function of green nanoparticles in liver therapies is discussed.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 6","pages":"89-116"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10019091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lignin-Based Nanomaterials as Drug Delivery Vehicles: A Review. 木质素基纳米药物递送载体研究进展

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022041829

Tahmidul Islam Aquib

引用次数: 0

A Review on Recent Advances in Mannose-Functionalized Targeted Nanocarrier Delivery Systems in Cancer and Infective Therapeutics. 甘露糖功能化靶向纳米载体递送系统在癌症和感染治疗中的最新进展。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022041853

Vasanti Suvarna, Niserga Sawant, Namita Desai

{"title":"A Review on Recent Advances in Mannose-Functionalized Targeted Nanocarrier Delivery Systems in Cancer and Infective Therapeutics.","authors":"Vasanti Suvarna, Niserga Sawant, Namita Desai","doi":"10.1615/CritRevTherDrugCarrierSyst.2022041853","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022041853","url":null,"abstract":"Unmodified nanocarriers used in the chemotherapy of cancers and various infectious diseases exhibit prolonged blood circulation time, prevent enzymatic degradation and increase chemical stability of encapsulated therapeutics. However, off-target effect and lack of specificity associated with unmodified nanoparticles (NPs) limit their applications in the health care system. Mannose (Man) receptors with significant overexpression on antigen-presenting cells and macrophages are among the most admired targets for cancer and anti-infective therapeutics. Therefore, development of Man functionalized nanocarriers targeting Man receptors, for target specific drug delivery in the chemotherapy have been extensively studied. Present review expounds diverse Man-conjugated NPs with their potential for targeted drug delivery, improved biodistribution profiles and localization. Additionally, the review gives detailed account of the interactions of mannosylated NPs with various biological systems and their characterization not discussed in earlier published reports is discussed.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 2","pages":"43-82"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Recent Advances and Prospects for Plant Gum-Based Drug Delivery Systems: A Comprehensive Review. 植物胶基给药系统的研究进展与展望

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022042252

Minkal Tuteja, Kalpana Nagpal

引用次数: 0

Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer. 用纳米治疗方法为器官封闭的晚期阉割耐药前列腺癌提供化疗和基因治疗。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022043827

Satish Sharma, Supriya D Mahajan, Kent Chevli, Stanley A Schwartz, Ravikumar Aalinkeel

{"title":"Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer.","authors":"Satish Sharma, Supriya D Mahajan, Kent Chevli, Stanley A Schwartz, Ravikumar Aalinkeel","doi":"10.1615/CritRevTherDrugCarrierSyst.2022043827","DOIUrl":"10.1615/CritRevTherDrugCarrierSyst.2022043827","url":null,"abstract":"Treatments for late-stage prostate cancer (CaP) have not been very successful. Frequently, advanced CaP progresses to castration-resistant prostate cancer (CRPC), with 50#37;-70% of patients developing bone metastases. CaP with bone metastasis-associated clinical complications and treatment resistance presents major clinical challenges. Recent advances in the formulation of clinically applicable nanoparticles (NPs) have attracted attention in the fields of medicine and pharmacology with applications to cancer and infectious and neurological diseases. NPs have been rendered biocompatible, pose little to no toxicity to healthy cells and tissues, and are engineered to carry large therapeutic payloads, including chemo- and genetic therapies. Additionally, if required, targeting specificity can be achieved by chemically coupling aptamers, unique peptide ligands, or monoclonal antibodies to the surface of NPs. Encapsulating toxic drugs within NPs and delivering them specifically to their cellular targets overcomes the problem of systemic toxicity. Encapsulating highly labile genetic therapeutics such as RNA within NPs provides a protective environment for the payload during parenteral administration. The loading efficiencies of NPs have been maximized while the controlled their therapeutic cargos has been released. Theranostic (\"treat and see\") NPs have developed combining therapy with imaging capabilities to provide real-time, image-guided monitoring of the delivery of their therapeutic payloads. All of these NP accomplishments have been applied to the nanotherapy of late-stage CaP, offering a new opportunity for a previously dismal prognosis. This article gives an update on current developments in the use of nanotechnology for treating late-stage, castration-resistant CaP.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 4","pages":"69-100"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11007628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9475172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis. 目前治疗特应性皮炎的药物及配方研究进展。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2023042979

Keerthi Atluri, Srikanth Manne, Vijendra Nalamothu, Alon Mantel, Purnendu K Sharma, R Jayachandra Babu

{"title":"Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis.","authors":"Keerthi Atluri, Srikanth Manne, Vijendra Nalamothu, Alon Mantel, Purnendu K Sharma, R Jayachandra Babu","doi":"10.1615/CritRevTherDrugCarrierSyst.2023042979","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023042979","url":null,"abstract":"Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a complex pathophysiology. Treatment of AD remains challenging owing to the presence of a wide spectrum of clinical phenotypes and limited response to existing therapies. However, recent genetic, immunological, and pathophysiological insights into the disease mechanism resulted in the invention of novel therapeutic drug candidates. This review provides a comprehensive overview of current therapies and assesses various novel drug delivery strategies currently under clinical investigation. Further, this review majorly emphasizes on various topical treatments including emollient therapies, barrier repair agents, topical corticosteroids (TCS), phosphodiesterase 4 (PDE4) inhibitors, calcineurin inhibitors, and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway inhibitors. It also discusses biological and systemic therapies, upcoming treatments based on ongoing clinical trials. Additionally, this review scrutinized the use of pharmaceutical inactive ingredients in the approved topical dosage forms for AD treatment.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 6","pages":"1-87"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10010645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Advances in Teriparatide Delivery by-virtue-of Novel Drug Delivery Approaches for the Management of Osteoporosis. 特立帕肽在骨质疏松症治疗中的新给药途径研究进展。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2023045014

Sagar Salave, Dhwani Rana, Kedar Prayag, Srushti Shah, Garima Rawat, Nitish Sharma, Anil B Jindal, Rikin Patel, Derajram Benival

{"title":"Recent Advances in Teriparatide Delivery by-virtue-of Novel Drug Delivery Approaches for the Management of Osteoporosis.","authors":"Sagar Salave, Dhwani Rana, Kedar Prayag, Srushti Shah, Garima Rawat, Nitish Sharma, Anil B Jindal, Rikin Patel, Derajram Benival","doi":"10.1615/CritRevTherDrugCarrierSyst.2023045014","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023045014","url":null,"abstract":"Osteoporosis is a bone incapacitating malady which globally accounts for over hundred million fractures annually. Therapeutic interventions for management of osteoporosis are divided as antiresorptive agents and osteoanabolic agents. Teriparatide is the only osteoana-bolic peptide which is available world-wide for the treatment of osteoporosis. It is administered as a daily subcutaneous injection for the treatment of osteoporosis which results in both poor patient compliance and increase in the cost of the therapy. Even after 20 years of clinical use of teriparatide, no formulation of teriparatide has yet been translated from lab to clinic which can be delivered by non-invasive route The present review critically discusses attempts made by the researchers for efficient delivery of teriparatide through various non-invasive routes such as oral, nasal, pulmonary, and transdermal route. It also discusses long-acting injectable formulations of teriparatide to improve patient compliance. Understanding on the pharmacology of teriparatide highlights the enhanced effectiveness of intermittent/pulsatile mode of teriparatide delivery which has also been elaborated. In addition, targeted delivery of teriparatide using different bone specific targeting moieties has been also discussed.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 5","pages":"93-123"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9898040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Overview on Macrophage Targeting: A Promising Approach. 巨噬细胞靶向研究综述:一个有前途的方法。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022038827

Venkata Deepthi Vemuri, Rekharani Kushwaha, Gollu Gowri, Nalini Mathala, Swathi Nalla, Sasikala Allam, Gurijala Lekhya

{"title":"An Overview on Macrophage Targeting: A Promising Approach.","authors":"Venkata Deepthi Vemuri, Rekharani Kushwaha, Gollu Gowri, Nalini Mathala, Swathi Nalla, Sasikala Allam, Gurijala Lekhya","doi":"10.1615/CritRevTherDrugCarrierSyst.2022038827","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022038827","url":null,"abstract":"Macrophages are immuno cells with high flexibility among hematopoietic system. Macrophages are tangled with many diseases like chronic inflammatory, atherosclerosis, autoimmune, and cancer. Macrophages play a major role in developing the inflammation and meanwhile resolving the damage occurred during these disease conditions. Therefore, the use of macrophages in targeted drug delivery appeared to be a promising approach in modifying the microenvironment of inflammatory diseases. The macrophages with cellular backpacks loaded with drugs were appeared to be the effective drug transporter to the brain inflammation. Till date, among the different carrier systems emerged among macrophage targeting: liposomes, microspheres, nanoparticles, and dendrimers were extensively studied. The physicochemical properties like components, lipophilicity, hydrophilicity, ligand presence, and concentration of these carriers may vary the efficacy and specificity of drug targeting to macrophages. The present review provides an insight into M1 and M2 macrophages characteristics, mainly discussed the role of macrophages in regulating several inflammatory diseases. This article underlines the current status and application of different carriers for targeted drug delivery to macrophages along with their efficacy and specificity. In general, the targeted drug delivery was achieved using the carrier systems by removing the intrinsic pathway and bio protection which is offered to the therapeutic molecules. Further, the review also summarizes the newer approaches for macrophage targeting with a brief overview on recent advances and future prospects.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 5","pages":"47-92"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9901988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0